GLP1R agonists like lixisenatide, exenatide, or semaglutide limit the progression of motor dysfunction in Parkinson’s disease.
AstraZeneca
Posted inClinical Trials, COVID-19, Infections, New Drugs
Nexsheld: Updated Evusheld for Effective Vaccine-Free COVID-19 Protection
Sipavibart injection every six months for reliable prevention of COVID-19.
Posted inCOVID-19, Infections, New Drugs, Regulatory
Pemgarda: For COVID-19 Protection Instead of Vaccines
Pemivibart every three months. For those who cannot receive the COVID-19 vaccine.
Posted inNew Drugs, Oncology, Regulatory
Datroway/Datverzo: Groundbreaking New Way to Treat Lung Cancer
Datopotamab deruxtecan for the treatment of unresectable NSCLC after failure of first-line therapy.
Posted inCardiology, Clinical Trials, In the Pipeline, Metabolism
Enlicitide: Very Strong Pill Against ‘Bad’ Cholesterol
The oral drug by Merck & Co. smashes all competitors for the treatment and prevention of atherosclerosis.
Posted inClinical Trials, Metabolism
Dorzagliatin: Drug That Can “Cure” Diabetes
Hua Medicine has figured out how to bring type 2 diabetes mellitus into long-term and sustained remission.
Posted inInfections, New Drugs, Regulatory
Beyfortus: Effective Protection for Infants Against Respiratory Syncytial Virus
One injection of nirsevimab reliably protects newborns against the development of RSV-associated lower respiratory tract infections.